Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Depreciation & Amortization (CF) (2021 - 2025)

Historic Depreciation & Amortization (CF) for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $28.0 million.

  • Rxo's Depreciation & Amortization (CF) fell 1515.15% to $28.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $116.0 million, marking a year-over-year increase of 3333.33%. This contributed to the annual value of $116.0 million for FY2025, which is 3333.33% up from last year.
  • Per Rxo's latest filing, its Depreciation & Amortization (CF) stood at $28.0 million for Q4 2025, which was down 1515.15% from $26.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Depreciation & Amortization (CF) registered a high of $33.0 million during Q4 2024, and its lowest value of $15.0 million during Q4 2023.
  • Moreover, its 5-year median value for Depreciation & Amortization (CF) was $21.0 million (2022), whereas its average is $22.1 million.
  • In the last 5 years, Rxo's Depreciation & Amortization (CF) crashed by 3043.48% in 2023 and then surged by 12000.0% in 2024.
  • Quarter analysis of 5 years shows Rxo's Depreciation & Amortization (CF) stood at $19.0 million in 2021, then rose by 10.53% to $21.0 million in 2022, then fell by 28.57% to $15.0 million in 2023, then surged by 120.0% to $33.0 million in 2024, then decreased by 15.15% to $28.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $28.0 million for Q4 2025, versus $26.0 million for Q3 2025 and $30.0 million for Q2 2025.